Cantor Fitzgerald raised the firm’s price target on Zevra Therapeutics (ZVRA) to $29 from $25 and keeps an Overweight rating on the shares. Miplyffa stands a good chance of approval in the EU, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics initiated with a Buy at H.C. Wainwright
- Zevra Therapeutics Elects New Directors at Annual Meeting
- Zevra announces 3 proxy advisory firms recommended vote ‘FOR’ Dixon, Favorito
- Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
- Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating